Last updated: September 5, 2026
Amitriptyline hydrochloride/perphenazine is a legacy fixed-dose antidepressant-antipsychotic combination historically marketed in the United States as Triavil. Its commercial position has deteriorated to a low-volume generic or discontinued-product profile. The original combination-product patents and regulatory exclusivities have long expired, no meaningful active patent barrier is apparent, and public companies do not report material product-level revenue for the combination. Current commercial value resides primarily in the separate generic markets for amitriptyline and perphenazine.
What is the current market status of amitriptyline hydrochloride and perphenazine?
The fixed-dose combination is not a significant active branded market in the United States. Triavil and equivalent amitriptyline/perphenazine tablets have been discontinued or become commercially unavailable in many channels. The individual components remain available as low-cost generic products.
| Product |
Current commercial position |
Primary use category |
Market structure |
| Amitriptyline hydrochloride |
Widely available generic |
Depression historically; neuropathic pain, migraine prevention and other off-label uses |
Multiple generic manufacturers |
| Perphenazine |
Generic, limited-volume product |
Schizophrenia and severe nausea or vomiting |
Smaller generic supplier base |
| Amitriptyline/perphenazine fixed-dose combination |
Legacy or discontinued product |
Historical treatment of depressive symptoms with anxiety or agitation |
Little or no active branded presence |
The combination is pharmacologically dated. Amitriptyline is a tricyclic antidepressant with anticholinergic and sedating effects. Perphenazine is a first-generation phenothiazine antipsychotic. Their combined safety burden, including sedation, orthostatic hypotension, anticholinergic effects, extrapyramidal symptoms, tardive dyskinesia and cardiac risk, limits use relative to newer antidepressant and antipsychotic therapies.
The FDA-approved labeling for the combination reflects an older treatment model and does not create a modern growth platform. Current clinical practice generally uses the two agents separately, when either is selected, rather than relying on the fixed-dose product.
What patents protect amitriptyline hydrochloride and perphenazine?
No commercially meaningful unexpired composition-of-matter patent protects the amitriptyline/perphenazine combination in the United States.
Amitriptyline and perphenazine were developed and marketed decades ago. Their original active-ingredient patents expired long before the current generic era. Any historical patents covering the fixed-dose combination, tablet composition or early methods of treatment also would have expired under the ordinary patent term framework.
| Patent category |
Current relevance |
| Amitriptyline composition patents |
Expired |
| Perphenazine composition patents |
Expired |
| Fixed-dose combination patents |
Expired or commercially irrelevant |
| Historical formulation patents |
Expired |
| Method-of-use patents for the legacy combination |
No material current barrier identified |
| Manufacturing patents |
No identified barrier capable of supporting market exclusivity |
The product does not have the patent profile of a modern small-molecule launch. There is no apparent pathway to extending exclusivity through a new chemical entity, pediatric extension or meaningful formulation patent.
When did amitriptyline/perphenazine lose exclusivity?
The combination lost meaningful exclusivity decades ago. The relevant protection period predates the modern Hatch-Waxman framework and current Orange Book-centered patent strategy.
The practical exclusivity timeline is:
| Period |
Commercial event |
| 1960s and later |
Amitriptyline/perphenazine combination marketed as Triavil and related products |
| 1970s-1980s |
Original product and ingredient exclusivities expired |
| 1980s-2000s |
Generic substitution and declining use increased |
| 2000s-2010s |
Fixed-dose combination became commercially marginal |
| Current market |
Separate generic ingredients remain available; fixed-dose combination has limited or no active commercial presence |
The precise expiration dates for early patents are less important to current market analysis because any relevant exclusivity has been absent for many years. No remaining patent term appears capable of delaying a generic launch.
What is the Orange Book status of amitriptyline/perphenazine?
The fixed-dose combination does not have a meaningful current Orange Book position comparable with an active branded reference product.
The FDA Orange Book is most commercially relevant when an NDA holder maintains a marketed reference product and lists patents or regulatory exclusivities that affect ANDA approval. Amitriptyline/perphenazine does not present that structure today. The product’s principal barriers are commercial and operational rather than legal.
The relevant regulatory conclusions are:
- No active new chemical entity exclusivity remains.
- No current market exclusivity is associated with the legacy combination.
- No material patent-listed delay to ANDA approval is apparent.
- Any generic approval would face limited legal obstruction if a sponsor pursued the product.
- The absence of a robust reference-product market may make regulatory and commercial execution less attractive than patent risk.
FDA records distinguish products discontinued for commercial reasons from products withdrawn for safety or effectiveness. A discontinued listing does not necessarily establish a safety withdrawal. The combination’s limited availability is better understood as a commercial and clinical obsolescence issue than as the result of a single patent event.
Are there Paragraph IV challenges involving amitriptyline/perphenazine?
No significant current Paragraph IV litigation is associated with the legacy combination.
Paragraph IV challenges are generally economically rational when a branded reference product has substantial sales and a generic applicant can capture a large market after invalidating or avoiding listed patents. Those conditions do not exist for amitriptyline/perphenazine.
| Paragraph IV factor |
Assessment |
| Active branded product |
Weak or absent |
| Listed blocking patents |
None of material current significance identified |
| Potential 180-day exclusivity value |
Low |
| Expected litigation damages |
Low |
| Commercial incentive to challenge |
Minimal |
| Current litigation profile |
No material active challenge identified |
A sponsor could still pursue an ANDA or other regulatory route if it identified sufficient demand. The absence of Paragraph IV litigation does not mean the product is legally unavailable. It indicates that patent litigation is unlikely to be the principal market-entry issue.
What formulations are protected by patents?
No active formulation patent appears to support exclusivity for the historical amitriptyline/perphenazine tablets.
The legacy product used conventional oral tablets containing fixed strengths of the two active ingredients. Historical strengths included combinations such as 2 mg or 4 mg of perphenazine with 25 mg or 50 mg of amitriptyline hydrochloride. These conventional dosage forms do not present a technically differentiated delivery system.
There is no established current patent moat around:
- Extended-release delivery
- Abuse-deterrent technology
- Long-acting injectable delivery
- Transdermal delivery
- Nanoparticle formulation
- Gastroretentive delivery
- Enantiomeric or metabolite-specific formulations
A new formulation could theoretically create patentable subject matter, but it would be a new product-development project rather than a continuation of the legacy combination’s commercial franchise. It would also face clinical, regulatory and reimbursement challenges because physicians can prescribe the two ingredients separately.
How strong is the patent estate for the combination?
The patent estate is commercially weak and effectively exhausted.
| Patent-strength criterion |
Assessment |
| Composition-of-matter protection |
None remaining |
| Patent term remaining |
None of practical importance |
| Formulation differentiation |
Low |
| Method-of-use protection |
Low |
| Manufacturing complexity |
Low to moderate |
| Freedom-to-operate risk |
Low based on expired legacy rights |
| Ability to support premium pricing |
Very low |
The most relevant intellectual-property risk for a new manufacturer would not be infringement of legacy patents. It would be regulatory compliance, product quality, supply continuity and the ability to obtain economically viable distribution.
How does the combination compare with separate generic amitriptyline and perphenazine?
The separate products have materially stronger commercial positions because each has an established prescribing base and can be used across multiple indications.
| Factor |
Fixed-dose combination |
Amitriptyline alone |
Perphenazine alone |
| Prescribing flexibility |
Low |
High |
High |
| Available indications |
Narrow legacy positioning |
Broad off-label and specialty use |
Established antipsychotic and antiemetic uses |
| Generic competition |
Limited or discontinued |
High |
Moderate to high |
| Clinical familiarity |
Low |
High |
Moderate |
| Formulary relevance |
Low |
Moderate |
Selective |
| Pricing power |
Negligible |
Negligible to low |
Low |
| Development opportunity |
Requires reformulation or repositioning |
Limited |
Limited |
Amitriptyline has a durable generic market because clinicians use it for neuropathic pain, migraine prevention and sleep-related symptoms despite its historical antidepressant label. Perphenazine retains a smaller but identifiable market in schizophrenia and related psychiatric treatment. The combination has fewer reasons to be selected because clinicians can titrate each drug independently and avoid exposing patients to both agents when only one is needed.
What is the financial trajectory of amitriptyline/perphenazine?
The fixed-dose combination has no identifiable public-company revenue trajectory. Product-level sales were not separately disclosed in recent annual reports by major pharmaceutical companies, and the product’s economic contribution appears immaterial relative to the companies’ consolidated portfolios.
The likely financial trajectory is:
- Legacy branded revenue: Declined after generic entry and the emergence of newer antidepressants and antipsychotics.
- Generic substitution: Reduced unit economics and shifted value from brand promotion to low-cost manufacturing.
- Channel contraction: Reduced pharmacy and wholesaler demand made the fixed-dose product less attractive to manufacturers.
- Current state: Revenue is likely minimal, intermittent or absent in the U.S. fixed-dose market.
- Residual value: Concentrated in the separate amitriptyline and perphenazine products, not the combination.
Public pricing databases and government reimbursement data generally provide stronger visibility for the separate generic ingredients than for the discontinued combination. Generic prices vary by strength, package size, supplier, wholesaler contracts and pharmacy channel. Those variables prevent a reliable product-level revenue estimate without proprietary prescription and net-sales data.
Revenue exposure for manufacturers
The combination does not appear to represent material revenue exposure for major pharmaceutical companies. Its main financial characteristics are:
- Low average selling price
- Limited prescription volume
- Weak brand recognition
- No patent-supported premium
- High substitution risk
- Limited promotional return
- Potentially uneven supply economics
A manufacturer could earn small niche revenue if it became one of few suppliers. That opportunity would depend on persistent demand from patients stabilized on the combination, institutional purchasing and competitor shortages. It would not constitute a conventional branded growth opportunity.
What generic launch scenarios exist?
A new generic launch would face low patent risk but uncertain commercial demand.
| Scenario |
Probability profile |
Commercial result |
| Single supplier reintroduces the combination |
Possible if a supply gap exists |
Temporary niche pricing, limited scale |
| Multiple suppliers enter |
Possible if demand is documented |
Rapid price erosion |
| Product remains unavailable |
Likely if demand does not cover manufacturing and regulatory costs |
No meaningful market recovery |
| Reformulated or modified-release product launches |
Low near-term probability |
Requires new clinical and regulatory investment |
| Separate generic ingredients continue |
High probability |
Main enduring market pathway |
The principal launch barrier is not patent infringement. It is whether the expected prescription base can support formulation work, stability studies, quality systems, FDA filing costs, commercial packaging and distribution.
Which companies are challenging or competing in the market?
There is no active branded competitive field around the fixed-dose combination comparable with modern specialty drugs. Competition is fragmented among generic suppliers of the individual ingredients. Supplier participation can change as companies discontinue low-margin products or respond to shortages.
The competitive landscape includes:
- Generic manufacturers of amitriptyline hydrochloride tablets
- Generic manufacturers of perphenazine tablets
- Contract manufacturers capable of low-volume oral solids
- Pharmacy distributors serving institutional or specialty demand
- Alternative antidepressant and antipsychotic therapies
The key competitors are not necessarily other fixed-dose products. They include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, atypical antipsychotics, newer agents for neuropathic pain and nonpharmacologic psychiatric care.
What manufacturing and intellectual-property barriers exist?
Manufacturing is technically conventional but commercially sensitive. The product requires standard oral-solid-dose capabilities, analytical testing, content uniformity controls, stability data and compliance with current good manufacturing practice requirements.
Potential operational barriers include:
- Low batch volumes
- Separate active-ingredient sourcing
- Stability and impurity control
- Limited active pharmaceutical ingredient suppliers
- Packaging and labeling costs
- Drug-shortage management
- Low inventory turnover
- Regulatory maintenance costs
Perphenazine is a potent active ingredient that requires appropriate containment and worker-safety controls. Amitriptyline is easier to manufacture at scale, but combining both ingredients adds testing, validation and supply-chain complexity without necessarily creating pricing power.
No manufacturing patent barrier appears to be decisive. The greater risk is that a company cannot achieve acceptable cost per batch at the available market volume.
What regulatory and biosimilar risks apply?
Biosimilar risk does not apply. Amitriptyline and perphenazine are synthetic small molecules, not biologics.
The relevant regulatory pathways are abbreviated small-molecule pathways, principally ANDA-based generic approval where an appropriate reference product and regulatory framework are available. A new or modified formulation could require a different regulatory strategy depending on its claims, dosage form and equivalence requirements.
Regulatory risk is concentrated in:
- Demonstrating pharmaceutical equivalence
- Establishing bioequivalence
- Maintaining manufacturing quality
- Managing discontinued-reference-product issues
- Securing a stable API supply
- Updating labeling and safety information
The FDA’s treatment of discontinued products and reference standards can affect development feasibility even when patent protection has expired.
What litigation and settlement agreements affect the product?
No material current patent litigation or settlement agreement is associated with the legacy fixed-dose combination. The absence of disputes is consistent with the product’s expired exclusivity and low commercial value.
Potential legal exposure is more likely to arise from ordinary product-liability, labeling, manufacturing or distribution issues than from Orange Book patent litigation. Those risks are not equivalent to a market-exclusion risk and generally would not support a premium valuation for the product.
What is the geographic market outlook?
The United States has the clearest evidence of commercial decline for the fixed-dose combination. Other markets may retain limited use because of legacy prescribing, differences in generic availability or local treatment practices.
| Region |
Outlook |
| United States |
Fixed-dose product commercially marginal; separate generics remain available |
| Europe |
Country-specific availability; likely limited and fragmented |
| Emerging markets |
Possible legacy demand, but low pricing and uneven registration |
| Institutional markets |
Potential episodic demand if hospitals or pharmacies seek a replacement |
| Global branded opportunity |
Very low |
International opportunity would depend on local registrations, reference-product requirements, reimbursement policies and the presence of competing separate ingredients. A country with limited access to psychiatric medicines could support niche demand, but likely at low prices.
Key Takeaways
- Amitriptyline hydrochloride/perphenazine is a legacy fixed-dose combination historically sold as Triavil.
- The combination has no meaningful remaining composition, formulation or method-of-use patent protection.
- Current commercial activity is weak, discontinued or highly limited in the United States.
- No material Paragraph IV litigation or active patent challenge is associated with the product.
- Separate generic amitriptyline and perphenazine products have stronger ongoing demand than the fixed-dose combination.
- Public companies do not disclose material product-level revenue for the combination.
- The commercial barrier to reentry is low patent risk but uncertain demand and poor generic economics.
- Biosimilar risk is irrelevant because both active ingredients are synthetic small molecules.
- Any residual value is niche, supply-driven and unlikely to support a premium pharmaceutical valuation.
FAQs
Is Triavil still available in the United States?
Triavil is generally regarded as discontinued or commercially unavailable in the United States. Availability may vary by supplier, pharmacy inventory and limited legacy distribution.
Can amitriptyline and perphenazine be prescribed separately?
Yes. Separate generic tablets are the more commercially relevant treatment pathway and allow physicians to adjust each active ingredient independently.
Does amitriptyline/perphenazine have Orange Book patent protection?
No material current patent protection appears to block generic competition for the legacy combination.
Could a company relaunch amitriptyline/perphenazine?
A relaunch is technically possible, but commercial success would depend on proving sufficient demand, obtaining regulatory approval and maintaining profitable supply despite low pricing.
Is the combination a viable pharmaceutical licensing asset?
As a standalone fixed-dose product, it is unlikely to be an attractive licensing asset. Value would require a differentiated formulation, a new clinical use, reliable shortage-driven demand or a broader portfolio strategy.
References
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. FDA.
-
U.S. Food and Drug Administration. (2024). National Drug Code Directory. FDA.
-
U.S. Food and Drug Administration. (2024). Drug products discontinued from marketing. FDA.
-
U.S. National Library of Medicine. (2024). DailyMed: Amitriptyline hydrochloride and perphenazine labeling. National Library of Medicine.
-
U.S. National Library of Medicine. (2024). DailyMed: Amitriptyline hydrochloride labeling. National Library of Medicine.
-
U.S. National Library of Medicine. (2024). DailyMed: Perphenazine labeling. National Library of Medicine.
